PDCD1 and cancer: The commonly used immune checkpoint inhibitors in cancer therapies are designed for inhibiting receptors (e.g., programmed cell death-1 (PD-1) receptor) typically expressed in T-cells and the ligand (e.g., PD-L1) expressed by cancer cells [105,106,107].